Skip to Main content Skip to Navigation
Journal articles

Bone morphogenetic protein-9 is a circulating vascular quiescence factor.: BMP9 is present in serum and inhibits angiogenesis

Laurent David 1 Christine Mallet 1 Michelle Keramidas 1 Noël Lamandé 2 Jean-Marie Gasc 2 Sophie Dupuis-Girod 3 Henri Plauchu 3 Jean-Jacques Feige 1 Sabine Bailly 1, *
* Corresponding author
2 Angiogénèse embryonnaire et pathologique
UPMC - Université Pierre et Marie Curie - Paris 6, CIRB - Centre interdisciplinaire de recherche en biologie, INSERM - Institut National de la Santé et de la Recherche Médicale : U833
Abstract : Angiogenesis is a complex process, requiring a finely tuned balance between numerous stimulatory and inhibitory signals. ALK1 (activin receptor like-kinase 1) is an endothelial-specific type 1 receptor of the transforming growth factor-beta receptor family. Heterozygotes with mutations in the ALK1 gene develop hereditary hemorrhagic telangiectasia type 2 (HHT2). Recently, we reported that bone morphogenetic protein (BMP)9 and BMP10 are specific ligands for ALK1 that potently inhibit microvascular endothelial cell migration and growth. These data lead us to suggest that these factors may play a role in the control of vascular quiescence. To test this hypothesis, we checked their presence in human serum. We found that human serum induced Smad1/5 phosphorylation. To identify the active factor, we tested neutralizing antibodies against BMP members and found that only the anti-BMP9 inhibited serum-induced Smad1/5 phosphorylation. The concentration of circulating BMP9 was found to vary between 2 and 12 ng/mL in sera and plasma from healthy humans, a value well above its EC(50) (50 pg/mL). These data indicated that BMP9 is circulating at a biologically active concentration. We then tested the effects of BMP9 in 2 in vivo angiogenic assays. We found that BMP9 strongly inhibited sprouting angiogenesis in the mouse sponge angiogenesis assay and that BMP9 could inhibit blood circulation in the chicken chorioallantoic membrane assay. Taken together, our results demonstrate that BMP9, circulating under a biologically active form, is a potent antiangiogenic factor that is likely to play a physiological role in the control of adult blood vessel quiescence.
Document type :
Journal articles
Complete list of metadata

Cited literature [10 references]  Display  Hide  Download
Contributor : Sabine Bailly <>
Submitted on : Friday, August 29, 2008 - 9:01:47 AM
Last modification on : Saturday, April 24, 2021 - 6:46:03 PM
Long-term archiving on: : Friday, May 28, 2010 - 5:16:42 PM



Laurent David, Christine Mallet, Michelle Keramidas, Noël Lamandé, Jean-Marie Gasc, et al.. Bone morphogenetic protein-9 is a circulating vascular quiescence factor.: BMP9 is present in serum and inhibits angiogenesis. Circulation Research, American Heart Association, 2008, 102 (8), pp.914-22. ⟨10.1161/CIRCRESAHA.107.165530⟩. ⟨inserm-00277236⟩



Record views


Files downloads